title: [Post-anesthetic hepatitis. The role of halothane and antimitotic combinations].
abstract: A 12 year old boy with Burkitt's lymphoma developed severe hepatitis with hepatomegaly, subclinical jaundice, and a small rise in body temperature, associated with an important rise in SGPT and fall in prothrombin titres, 6 days after anticancer chemotherapy and 24 hours after halothane anaesthesia. Hepatitis A and B serology remained negative. This hepatic failure explained perhaps the unusually severe vincristine toxicity which gave rise to a polyneuritis with important sequelae. The association of halothane hepatitis with antimitotic drugs appeared particularly dangerous, and halothane should probably be avoided in all patients been given or about to be given anticancer chemotherapy.
mesh_terms: D000769:Anesthesia, Inhalation; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D002051:Burkitt Lymphoma / Q000188:drug therapy; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology* / Q000473:pathology; D002648:Child; D004359:Drug Therapy, Combination; D006221:Halothane / Q000009:adverse effects*; D006801:Humans; D008297:Male
chemical_list: D000970:Antineoplastic Agents; D006221:Halothane
vernacular_title: Hépatite postanesthésique. Responsabilité de l'association halothane-antimitotiques.